Browse the evidence

Younger age, tirzepatide use, and GLP1 treatment naivety were identified as determinants of faster achievement of ≥10% weight loss.

Understanding these determinants can help tailor weight loss strategies for individuals.

Adding testosterone undecanoate to tirzepatide in late responders resulted in significantly greater body weight and fat mass reduction compared to tirzepatide monotherapy (P<0.05).

Clinicians may consider adding testosterone therapy to enhance weight loss outcomes in specific patient populations.

Testosterone undecanoate addition led to significant lean body mass recovery compared to tirzepatide monotherapy (66.1±3.1 kg vs. 63.4±3.0 kg, P<0.01).

Adding testosterone therapy may help preserve or enhance muscle mass in patients struggling with weight loss.

GLP-1 receptor agonists achieve clinically significant weight loss of 15–22.5% total body weight.

GLP-1 RAs can be considered effective options for achieving significant weight loss in obesity management.

GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists provide clinically meaningful weight loss of approximately 15%–21% at 68–72 weeks in major trials.

Practitioners can expect significant weight loss in patients using GLP-1 therapies over the specified duration.

Semaglutide reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% in adults with established cardiovascular disease.

GLP-1 therapies may also provide cardiovascular benefits, which is important for patient management.

Incretin-based therapies have transformed the management of obesity and type 2 diabetes, with GLP-1RAs achieving levels of weight loss that begin to narrow the gap with metabolic surgery in selected populations.

Practitioners should consider incretin-based therapies as effective options for weight management in patients with obesity and type 2 diabetes.

Participants using the program plus medication were more likely to achieve clinically significant weight loss, with odds ratios ranging from 1.46 to 2.57 for ≥5% weight loss across timepoints.

Integrating a behavioral support app with GLP-1 RA treatment can significantly enhance weight loss outcomes.

Medication type was the strongest determinant of weight loss over time, with tirzepatide producing greater early reductions.

Choosing the right GLP-1 RA can significantly impact weight loss success.

Chronic ketone ester intake may blunt overreaching symptoms during short-term endurance training overload.

Practitioners may consider ketone esters to mitigate overreaching in endurance training.

Adequate sleep duration of 7-9 hours per night is emphasized as foundational for recovery and adaptation in hypertrophy training.

Prioritize 7-9 hours of sleep per night to enhance recovery and muscle growth.

The first choice of therapy after lifestyle modification for T2D in obese individuals should be glucose-lowering agents that promote weight reduction or are weight neutral.

Healthcare providers should prioritize glucose-lowering agents that aid in weight management for obese T2D patients.

The intervention group experienced significantly greater improvements in diabetes treatment satisfaction and regimen-related diabetes stress compared to usual care.

Improving treatment satisfaction can enhance adherence to diabetes management strategies.

Weekly subcutaneous Semaglutide 2.4 mg results in a -13.7% body weight reduction.

Practitioners may consider Semaglutide as an effective weight loss therapy for women with preeclampsia.

Carbohydrate restriction leads to appetite reduction, weight loss, and improvements in glycemic and insulin control.

Practitioners may consider carbohydrate restriction as a strategy for managing obesity and T2DM.

Health coaching significantly reduced menopausal symptoms in postmenopausal and perimenopausal women, with a mean difference of -12.51 in menopausal scores from baseline to 4 months after the intervention.

Health coaching can be an effective intervention for reducing menopausal symptoms in women.

Health coaching improved quality of life in postmenopausal and perimenopausal women, with a mean difference of 4.13 from baseline to 4 months.

Health coaching can enhance the quality of life for women experiencing menopause.

Evidenzbasierte Therapieoptionen bei AP-assoziierter Gewichtszunahme umfassen Lebensstilveränderungen, Bewegungstherapie und medikamentöse Anpassungen.

Implementing lifestyle changes and considering medication adjustments can help manage weight gain in patients.

Evidenzbasierte Therapieoptionen bei AP-assoziierter Gewichtszunahme umfassen Lebensstilveränderungen, diätetische Maßnahmen, Bewegungstherapie, Dosisreduktion, Umstellung und Beendigung der Medikation sowie zusätzliche Therapien.

Implementing lifestyle and dietary changes can be effective in managing weight gain from medications.

A 10-minute daily yoga practice was significantly associated with changes in menstrual cycle symptoms and has the potential to mitigate some menstrual cycle symptoms and stress perception in an athletic cohort.

Incorporating a short daily yoga routine may help athletic women manage menstrual symptoms and stress.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces clinically significant weight loss (mean 6.2–12.9 kg) and glycemic control (HbA1c reduction -1.87 to -2.59%) in adults with type 2 diabetes, with efficacy increasing with dose up to 15 mg weekly.

Tirzepatide is a once-weekly injection for type 2 diabetes that helps lower blood sugar and lose weight. It starts at a low dose (2.5 mg) to minimize side effects like nausea, which usually improve over time. The dose can be increased every 4 weeks up to 15 mg based on tolerance and need. It is approved for adults with T2DM, especially those who are overweight or obese, and works by mimicking hormones that regulate blood sugar and appetite. Patients should follow dietary advice (smaller, low-fat meals) to manage GI side effects and monitor blood glucose, especially if taking other diabetes medications like insulin or sulfonylureas.

Tirzepatid (GIP/GLP-1 agonist) provides superior weight loss and glycemic control compared to Semaglutid in patients with Type 2 Diabetes and Obesity.

If oral medications and lifestyle changes are insufficient, Tirzepatid (10-15mg weekly) is currently the most effective pharmacological option for weight loss and blood sugar control in Type 2 Diabetes, outperforming Semaglutid. Discuss this with your doctor to see if it's appropriate for your specific health profile.

Semaglutide (2.4 mg weekly) and Liraglutide (3.0 mg daily) are effective pharmacological adjuncts for obesity, producing significant weight loss (15% and 8-10% respectively) when combined with lifestyle interventions.

For patients with BMI ≥ 30 (or ≥ 25 with comorbidities) who do not achieve goals with lifestyle changes alone, consider GLP-1 analogues. Semaglutide 2.4mg weekly yields ~15% weight loss; Liraglutide 3mg daily yields ~8-10%. These are adjuncts to, not replacements for, behavioral therapy.

Weekly subcutaneous tirzepatide (5-15 mg) produces significant, dose-dependent weight loss (-15% to -21%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly tirzepatide injections, combined with diet and exercise, can lead to significant weight loss (15-21%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.